Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial-Reference-Cited by-同舟云学术

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Published:2020-10-12 Issue:12 Volume:26 Page:1839-1844
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

van Dijk Nick,Gil-Jimenez Alberto^ORCID,Silina Karina^ORCID,Hendricksen Kees,Smit Laura A.,de Feijter Jeantine M.,van Montfoort Maurits L.,van Rooijen Charlotte,Peters Dennis,Broeks Annegien,van der Poel Henk G.,Bruining Annemarie,Lubeck Yoni,Sikorska Karolina,Boellaard Thierry N.,Kvistborg Pia,Vis Daniel J.,Hooijberg Erik^ORCID,Schumacher Ton N.^ORCID,van den Broek Maries^ORCID,Wessels Lodewyk F. A.^ORCID,Blank Christian U.^ORCID,van Rhijn Bas W.,van der Heijden Michiel S.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-020-1085-z.pdf

Reference35 articles.

1. Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).

2. Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).

3. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666–675 (2001).

4. Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241–249 (2014).

5. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 48, 202–205 (2005).

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tertiary lymphoid structures as potential biomarkers for cancer prediction and prognosis;International Immunopharmacology;2024-10

2. First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer;Journal of Clinical Oncology;2024-09-06

3. Immune checkpoint reprogramming via sequential nucleic acid delivery strategy optimizes systemic immune responses for gastrointestinal cancer immunotherapy;Cancer Letters;2024-09

4. Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis;The French Journal of Urology;2024-09

5. Macrophages and tertiary lymphoid structures as indicators of prognosis and therapeutic response in cancer patients;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09